1084 related articles for article (PubMed ID: 34299137)
21. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
[TBL] [Abstract][Full Text] [Related]
24. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
[TBL] [Abstract][Full Text] [Related]
25. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
26. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
27. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
28. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
E J; Xing J; Gong H; He J; Zhang W
Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
[TBL] [Abstract][Full Text] [Related]
29. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
30. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
31. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
Bellier J; Nokin MJ; Caprasse M; Tiamiou A; Blomme A; Scheijen JL; Koopmansch B; MacKay GM; Chiavarina B; Costanza B; Rademaker G; Durieux F; Agirman F; Maloujahmoum N; Cusumano PG; Lovinfosse P; Leung HY; Lambert F; Bours V; Schalkwijk CG; Hustinx R; Peulen O; Castronovo V; Bellahcène A
Cell Rep; 2020 Feb; 30(5):1400-1416.e6. PubMed ID: 32023458
[TBL] [Abstract][Full Text] [Related]
32. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
34. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
35. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.
Xu H; Liu Y; Cheng P; Wang C; Liu Y; Zhou W; Xu Y; Ji G
J Exp Clin Cancer Res; 2020 Dec; 39(1):283. PubMed ID: 33317596
[TBL] [Abstract][Full Text] [Related]
36. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
37. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
[TBL] [Abstract][Full Text] [Related]
38. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
39. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
Xing Y; Jing H; Zhang Y; Suo J; Qian M
Int J Biochem Cell Biol; 2020 Jan; 118():105643. PubMed ID: 31704502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]